

TABLE S1. Demographic and Baseline Clinical Characteristics

	Lersivirine 500 mg (N = 65)	Lersivirine 750 mg (N = 65)	Efavirenz (N = 63)
Male, n (%)	49 (75)	46 (71)	46 (73)
Mean age (range), years	36.5 (24–61)	35.7 (22–62)	36.3 (21–61)
Race, n (%)			
White	40 (62)	38 (58)	34 (54)
Black	18 (28)	22 (34)	24 (38)
Asian	6 (9)	0	2 (3)
Other	1 (2)	5 (8)	3 (5)
HIV-1 subtype, n (%)			
B	42 (65)	40 (62)	37 (59)
C	17 (26)	22 (34)	22 (35)
Other	6 (9)	3 (5)	4 (6)
Geographic region, n (%)*			
Group A	47 (72)	43 (66)	39 (62)
Group B	18 (28)	22 (34)	24 (38)
Plasma HIV-1 RNA at screening (log ₁₀ copies/mL), median (range)	4.7 (3.3–5.8)	4.7 (3.2–6.8)	4.7 (3.4–6.0)
Plasma HIV-1 RNA at screening			
<100,000 copies/mL, n (%)	45 (69)	44 (68)	41 (65)
≥100,000 copies/mL, n (%)	20 (31)	21 (32)	22 (35)
CD4 ⁺ cell count (cells/μL) at screening, median (range)	320 (183–806)	323 (200–955)	317 (122–553)

	Lersivirine 500 mg (N = 65)	Lersivirine 750 mg (N = 65)	Efavirenz (N = 63)
Baseline hepatitis B or C, n (%)			
None	64 (98)	63 (97)	58 (92)
B	0	0	1 (2)
C	1 (2)	2 (3)	4 (6)

*Group A includes EU, Latin America, Australia, and Canada; Group B includes South Africa.